Table 1.
Clinical and biological characteristics of patients at baseline, modalities of anti-HCV therapy, and immunosuppressive regimena
| Characteristic | Result |
||||
|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
| Age (yr), gender | 60, M | 50, M | 64, M | 67, M | 72, M |
| Body mass index (kg/m2) | 28.7 | 23.5 | 20.9 | 24.6 | 26.4 |
| Indication for LT | Cirrhosis | HCC | HCC | HCC | Cirrhosis |
| MELD score at listing | 24 | 10 | 12 | 22 | 28 |
| Calcineurin inhibitor | Cyclosporine | Cyclosporine | Cyclosporine | Tacrolimus | Tacrolimus |
| Other immunosuppressive drug(s) | Prednisone (5 mg QD) | Prednisone (5 mg QD), MMF (500 mg BID) | Everolimus (0.25 mg BID) | None | MMF (250 mg BID) |
| Baseline MELD score | 11 | 10 | 9 | 9 | 7 |
| Interval between LT and antiviral therapy (mo) | 62 | 3 | 36 | 105 | 36 |
| HCV genotype | 1b | 1a | 1b | 1b | 1b |
| Recipient IL-28b genotype | CC | CT | CT | CC | TT |
| Activity (A)/fibrosis stage (F) (METAVIR score) | A2/F4 | CH | A2/F2 | A2/F4 | A2/F3 |
| Baseline total bilirubin (μmol/liter) | 38 | 48 | 12 | 12 | 9 |
| Baseline GGT (IU/liter) | 179 | 3,227 | 391 | 319 | 38 |
| Baseline ALT (IU/liter) | 127 | 389 | 251 | 801 | 59 |
| Baseline INR | 1.2 | 1.0 | 0.9 | 1.1 | 0.9 |
| Baseline creatinine clearance (ml/min) | 111 | 114 | 50 | 57 | 67 |
| Baseline hemoglobin (g/dl) | 12.6 | 12.4 | 11.1 | 14.9 | 13.9 |
| Baseline neutrophil count (g/liter) | 5.9 | 1.6 | 1.8 | 3.2 | 2.3 |
| Baseline platelet count (g/liter) | 103 | 123 | 115 | 147 | 97 |
| Baseline albumin (g/liter) | 25.2 | 33.3 | 32.7 | 29.3 | 37.8 |
| Baseline HCV viral load (log10 IU/ml) | 6.30 | 7.97 | 7.1 | 6.58 | 6.33 |
| Peg-IFN dosage | Alpha-2b 1.4 μg/kg/week | Alpha-2b 1.3 μg/kg/week | Alpha-2a 180 μg/week | Alpha-2b 1.4 μg/kg/week | Alpha-2b 1.3 μg/kg/week |
| Ribavirin dosage | 7 mg/kg/day | 15 mg/kg/day | 12 mg/kg/day | 14 mg/kg/day | 8 mg/kg/day |
a
ALT, alanine aminotransferase; BID, twice a day (bis in die); CH, cholestatic hepatitis; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IL-28B, interleukin 28B; INR, international normalized ratio; LT, liver transplantation; M, male; MELD, model for end-stage liver disease; MMF, mycophenolate mofetil; Peg-IFN, pegylated interferon; QD, once a day (quaque die).